HIQA Kicks Off COVID-19 Vaccination Safety Review: What’s Next for Ireland?

Six years after SARS-CoV-2 emerged, Ireland’s COVID-19 vaccination strategy is entering a pivotal reassessment. The Health Information and Quality Authority (HIQA) has launched a comprehensive health technology assessment (HTA) to evaluate whether the current immunization program should adapt to the virus’s shift from pandemic to endemic phase. With the National Immunisation Advisory Committee (NIAC) already updating its recommendations in May 2025, this HTA will determine which population subgroups should remain prioritized—and which may no longer require state-funded vaccination. The stakes are high: balancing herd immunity thresholds against waning public trust, while navigating a post-pandemic healthcare landscape where resources are increasingly scrutinized.

Key Clinical Takeaways:

• The HIQA assessment will redefine Ireland’s COVID-19 vaccination eligibility for 2027–2028, focusing on clinical effectiveness, safety, and economic impact across high-risk subgroups.
• Epidemiological modeling will quantify Ireland’s residual burden of disease, accounting for evolving viral variants and declining vaccine-induced immunity over time.
• Healthcare providers must prepare for potential policy shifts, including updated consent protocols and supply chain adjustments for targeted booster campaigns.

From Pandemic to Endemic: The Evolving Risk Landscape

The transition from pandemic to endemic COVID-19 has reshaped the virus’s pathogenesis. Early variants like Alpha and Delta drove severe outcomes through high viral loads and immune evasion, but Omicron subvariants—particularly XBB.1.5 and its descendants—have demonstrated reduced severity while maintaining transmissibility. A 2025 meta-analysis in The Lancet Infectious Diseases [1] revealed that post-Omicron hospitalizations in high-income countries declined by 40% among vaccinated individuals compared to unvaccinated peers, though long COVID prevalence remained stubbornly high in immunocompromised populations. This duality—lower acute risk but persistent morbidity—is the crux of HIQA’s assessment.

“The challenge isn’t just whether vaccines still work, but who they work for. With Omicron subvariants, the risk calculus has shifted from mass protection to targeted shielding of those at highest residual risk.”

HIQA’s Methodology: Bridging Clinical Evidence and Policy

HIQA’s protocol outlines a three-pronged approach:

1. Epidemiological burden estimation: Modeling Ireland’s current COVID-19 morbidity and mortality, accounting for underreporting in the endemic phase. The authority will leverage real-world data from the HSE’s National COVID-19 Surveillance System, which has tracked over 12 million test results since 2020.
2. Clinical effectiveness review: A systematic review of post-marketing studies (e.g., NEJM’s 2025 analysis of mRNA vaccine durability [2]) to assess waning immunity against severe disease, hospitalization, and long COVID. Key variables include:

The table above reflects pre-print data from the CDC’s Vaccine Safety Datalink, though HIQA will prioritize peer-reviewed publications. Notably, the 30–45% reduction in long COVID underscores a critical gap: vaccines may not fully mitigate chronic symptoms, a finding that could influence NIAC’s subgroup prioritization.

Economic Modeling: The Hidden Cost of Inaction

HIQA’s assessment will also evaluate the economic impact of alternative vaccination strategies. A 2024 cost-effectiveness analysis in JAMA Network Open [3] estimated that targeted booster campaigns in high-risk groups (e.g., elderly, immunocompromised) could avert 1,200–1,800 hospitalizations annually in Ireland—at a cost of €40–60 million. However, the analysis assumed 80% uptake; real-world adherence has fluctuated between 55–70% in recent campaigns, introducing significant uncertainty.

“The most pressing question isn’t whether vaccines are cost-effective—it’s whether the public will accept them. Vaccine fatigue is a behavioral barrier that no HTA can fully quantify.”

Directory Triage: Who Needs to Act Now?

The HIQA assessment will likely trigger three critical adjustments for healthcare providers:

1. Updated consent protocols: Clinics administering COVID-19 vaccines should review informed consent documentation to reflect evolving risk-benefit profiles. For guidance, consult board-certified infectious disease specialists familiar with the latest NIAC recommendations.
2. Supply chain audits: Pharmacies and distributors may need to reallocate stock based on subgroup prioritization. Legal teams should engage healthcare compliance attorneys to navigate potential liability risks associated with vaccine allocation changes.
3. Long COVID clinics: Given the persistent morbidity in vaccinated individuals, providers should expand access to long COVID rehabilitation programs to address symptoms like post-exertional malaise and cognitive dysfunction.

The Road Ahead: A Precision Immunization Era

HIQA’s work signals the dawn of precision immunization, where vaccination strategies are tailored not just by age or risk, but by individual immune profiles. Emerging technologies—such as NIH’s adaptive immune monitoring—could soon enable clinicians to predict which patients will benefit most from boosters. For now, Ireland’s providers must brace for potential policy shifts, ensuring their practices align with evidence-based subgroup targeting.

One certainty remains: the conversation about COVID-19 vaccination is far from over. What’s changing is the who and why. For those on the front lines, the time to prepare is now.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.